Oxidative stress mediated cytotoxicity and apoptosis response of bismuth oxide (Bi2O3) nanoparticles in human breast cancer (MCF-7) cells

Ahamed, Maqusood; Akhtar, Mohd Javed; Khan, M.A. Majeed; Alrokayan, Salman A.; Alhadlaq, Hisham A.

doi:10.1016/j.chemosphere.2018.10.214

Cited by 90 publications

(64 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest concentration of BiONPs used, which is 0.5 mM could be considered as non-toxic and suitable to be applied as radiosensitizer due to the high percentage of cell viability after the treatment on all cell lines. However, in contrast to the present finding, cytotoxic response studies from previous reports that tested BiONPs of concentration around 0.215 mM (100 µg/mL) exhibited results of cell viability less than 80% 22,23. Temperature during the synthesis process could be one of the factors that influence cytotoxicity 22.…”

Section: Discussioncontrasting

confidence: 99%

<p>Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy</p>

Sisin¹,

Razak²,

Abidin³

et al. 2019

IJN

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate the potential of the synergetic triple therapeutic combination encompassing bismuth oxide nanoparticles (BiONPs), cisplatin (Cis), and high dose rate (HDR) brachytherapy with Ir-192 source in breast cancer and normal fibroblast cell line.MethodsIn vitro models of breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblast cell line (NIH/3T3) were employed. Cellular localization and cytotoxicity studies were conducted prior to inspection on the radiosensitization effects and generation of reactive oxygen species (ROS) on three proposed radiosensitizers: BiONPs, Cis, and BiONPs-Cis combination (BC). The optimal, non-cytotoxic concentration of BiONPs (0.5 mM) and the 25% inhibitory concentration of Cis (1.30 µM) were applied. The radiosensitization effects were evaluated by using a 0.38 MeV Iridium-192 HDR brachytherapy source over a prescribed dose range of 0 Gy to 4 Gy.ResultsThe cellular localization of BiONPs was visualized by light microscopy and accumulation of the BiONPs within the vicinity of the nuclear membrane was observed. Quantification of the sensitization enhancement ratio extrapolated from the survival curves indicates radiosensitization effects for MCF-7 and MDA-MB-231 when treated with BiONPs, Cis, and BC. However, NIH/3T3 cells exhibited contradictive behavior as it only reacted towards the BC combination. Nonetheless, the MCF-7 cell line loaded with BC shows the highest SER of 4.29. ROS production analysis, on the other hand, shows that Cis and BC radiosensitizers generated the highest free radicals in comparison to BiONPs alone.ConclusionA BiONPs-Cis combination was unveiled as a novel approach that offers promising radiosensitization enhancement that will increase the efficiency of tumor control while preserving the normal tissue at a reduced dose. This data is the first precedent to prove the synergetic implication of BiONPs, Cis, and HDR brachytherapy that will be beneficial for future chemoradiotherapy strategies in cancer care.

show abstract

Section: Discussioncontrasting

confidence: 99%

<p>Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy</p>

Sisin¹,

Razak²,

Abidin³

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Meanwhile, a study on erythrocytes revealed that a bismuth-based compound has antioxidant activity and offered protection against the toxicity by other particles [47]. Even though the latest investigation showed BiONPs could induce significantly high ROS but the lowest BiONPs concentration used was 50 µg/ml [48], while our study only used 0.5 µM or approximately 0.233 µg/ml of BiONPs as the highest concentration. Hence, it is suggested that the treatment of BiONPs on the cells in our study did not induce high oxidative stress and could be considered as biocompatible with the cells.…”

Section: )mentioning

confidence: 64%

Evaluation of Bismuth Oxide Nanoparticles as Radiosensitizer for Megavoltage Radiotherapy

Sisin¹,

Abidin²,

Amir³

et al. 2019

Int. J. Adv. Sci. Eng. Inf. Technol.

View full text Add to dashboard Cite

Metal-based nanoparticles such as gold, silver, platinum, and bismuth have been widely investigated for radiotherapeutic application. Basic understanding of the cellular interaction of the nanoparticles with the biological materials is crucial to ensure future clinical use. In this study, the cytotoxicity, cellular uptake, and generation of reactive oxygen species (ROS) induced by BiONPs were investigated prior elucidating the feasibility of BiONPs for radiotherapy application using megavoltage photon and electron beams. The BiONPs of diameter sizes 60, 70, 80 and 90 nm at concentrations within a range of 0.5 to 0.00005 mMol/L were tested on MCF-7, MDA-MB-231, and NIH/3T3 cells lines. The cytotoxicity results exhibit minimal cell death constituting less than 20 % of mortality on average. The ROS generation by BiONPs alone is found to be negligible as the ROS levels were slightly lower and higher than 100% of positive control. The increment of cellular nanoparticles uptake from a range of 1.50 % to 34.10 % indicates that BiONPs were internalized and bound to the surface of the cells. Sequencing from the results, 60 nm BiONPs are found to be the most suitable to be applied as a radiosensitizer in radiotherapy. Sensitization enhancement ratio (SER) quantified on MCF-7 cells demonstrated the highest enhancement from the highest concentration of BiONPs with SER of 2.29 and 1.42, for 10 MV photon beam and 6 MeV electron beam, respectively. In contrast to ROS production without radiation, the ROS induced from radiotherapy beams were found to be dose-dependent and play significant roles in radiosensitization effect. In conclusion, BiONPs could improve clinical radiotherapy, and further radiobiological characterization is crucial for future clinical translation.

show abstract

“…Ahamed et al. have found that Bi 2 O 3 NPs are actually bioactive and can provoke apoptosis in human breast cancer (MCF‐7) cells by elevating the intracellular oxidative stress . The in vitro study reveals that the mechanisms involve ROS overproduction, anti‐oxidant depletion, redox homeostasis imbalance, and alteration in the expression levels of various apoptosis‐related genes arising from the bioactivity of Bi 2 O 3 .…”

Section: Metallic Nanomaterialsmentioning

confidence: 99%

Inherent Chemotherapeutic Anti‐Cancer Effects of Low‐Dimensional Nanomaterials

Zhou

Chu

et al. 2019

Chemistry A European J

View full text Add to dashboard Cite

Low-dimensional nanomaterials (LDNs) are receiving increasing attention in cancert herapy owing to their unique properties, especially the large surfacea rea-tovolume ratio. LDNs such as metallicn anoparticles (NPs), hydroxyapatite NPs, graphene derivatives, and black phosphorus (BP) nanosheets have been proposed for drug delivery, photothermal/photodynamic therapies, andm ultimodal theranostict reatments. The therapeutic effectiveness is mainly based on the physical characteristics of LDNs, but their inherent bioactivity has not been fully capitalized. In this Minireview,r ecent advances in the anti-cancer effects of varioust ypes of LDNs with inherentc hemotherapeutic bioactivity are described and the bioactivity mechanismsa re discussed on the cellular and molecular levels.B P, one of the newesta nd exciting members of the LDN family,i sh ighlighted owing to the excellent inherent bioactivity,s electivity,a nd biocompatibility in cancert herapy.L DNs and related derivatives possess inherentb ioactivity and selective chemotherapeutic effects suggesting large potentiala sn anostructured anti-cancer agentsinc ancer therapy.

show abstract

Oxidative stress mediated cytotoxicity and apoptosis response of bismuth oxide (Bi2O3) nanoparticles in human breast cancer (MCF-7) cells

Cited by 90 publications

References 59 publications

<p>Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy</p>

<p>Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy</p>

Evaluation of Bismuth Oxide Nanoparticles as Radiosensitizer for Megavoltage Radiotherapy

Inherent Chemotherapeutic Anti‐Cancer Effects of Low‐Dimensional Nanomaterials

Contact Info

Product

Resources

About